How to Take ALUNBRIG® (brigatinib)

ALUNBRIG is a tablet that is taken orally once a day. Your healthcare provider will start you on a 90 mg dose of ALUNBRIG for the first 7 days of treatment.

After the first 7 days of treatment, your healthcare provider may increase your dose to 180 mg orally once daily. Be sure to review your ALUNBRIG dosing regimen with your healthcare team to ensure you are taking it correctly.

Week 1: Days 1 to 7
One 90 mg tablet taken once a day

Week 2+: Day 8 and beyond
One 180 mg tablet taken once a day

 

Infographic showing that ALUNBRIG can be taken as 1 tablet, once daily, with or without food.

AVOID EATING GRAPEFRUIT AVOID EATING GRAPEFRUIT
or drinking grapefruit juice during treatment with ALUNBRIG. Grapefruit may increase the amount of ALUNBRIG in your blood

STORE ALUNBRIG STORE ALUNBRIG
at room temperature of 68°F to 77°F (20°C to 25°C)


Things To Remember

Take ALUNBRIG exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking ALUNBRIG unless your healthcare provider tells you to.

  • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with ALUNBRIG if you develop side effects.
  • Swallow ALUNBRIG tablets whole. Do not crush or chew tablets.
  • If you miss a dose of ALUNBRIG, do not take the missed dose. Take your next dose at your regular time.
  • If you vomit after taking a dose of ALUNBRIG, do not take an extra dose. Take your next dose at your regular time.

Speak with your healthcare provider about any side
effects you may experience.

Take notes on how you are feeling and share them with your healthcare provider.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
You may also report side effects directly to Takeda Oncology at 1-844-817-6468 or GlobalOncologyMedinfo@Takeda.com.


Tips for Taking Your Medication Daily

Taking your medication every day is important. Consider these tips to help you stay on track and ensure that you are taking your daily dose of ALUNBRIG as prescribed.
 

  • Take your medication every day around the same time, such as when you have breakfast. Keep your pill box or medication bottle on or near the breakfast table.

  • Set an alarm in your house or on your mobile device to remind you to take your medication.

  • Designate a paper or online calendar to track your daily dose and mark each day with an X after you've taken your medication.

  • Ask a friend, family member, or caregiver to check in with you and remind you to take your medication.

  • Be sure to take your medication with you when you travel. If you are traveling by air, keep your medication in your carry-on bag. If you do leave it at home, call your healthcare provider right away. Your healthcare team may be able to get a new supply of ALUNBRIG to you at your new location through a nearby pharmacy.

  • Talk to your healthcare provider about all the possible side effects you may be experiencing. Your healthcare provider may be able to help you manage any side effects you may have while taking ALUNBRIG.

Learn About Possible Side Effects
FDA, Food and Drug Administration; ICD-10, International Classifications of Disease, Tenth Revision.

ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents of the US and US territories only.

ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents of the US and US territories only.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue +

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue +

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel +

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor-Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.


 
 
 

We use cookies to gather web statistics that help us improve our site. We store no personal details.
ACCEPT

Read More